Hypertension and knee osteoarthritis (OA) are frequent comorbidities. Nonsteroidal anti-inflammatory drugs (NSAIDs) are often used to relieve pain in such patients. In the last decade selective NSAIDs are used more commonly since they lead to less gastrointestinal complications. As has been shown, the treatment with NSAIDs may cause a mild rise of arterial blood pressure (BP). The influence of selective NSAIDs on BP, particularly in hypertensive patients has still to be investigated. The aim of this study was to determine arterial BP changes in patients suffering from stable arterial hypertension and knee OA and treated with rofecoxib or nabumetone. Two groups of patients with knee OA and stable arterial hypertension received either 25 mg rofecoxib once daily or namebutone 2000 mg once daily during the first week of treatment and 1000 mg for the following 3 weeks. Twenty-four hour arterial BP monitoring was performed prior to initiation of treatment and at the end of a 4-week period. The results were that no changes were found in
Introduction
Hypertension and knee osteoarthritis (OA) are common comorbidities among the elderly population. Nonsteroidal anti-inflammatory drugs (NSAIDs) are often used to relieve pain in such patients. Because of the untoward effect of non-selective NSAIDs on the upper gastrointestinal tract, mainly among the elderly population, 1 there is a trend to use NSAIDs of newer generation such as highly selective cyclooxygenase-2 (COX-2) inhibitors. These new COX-2 inhibitors (rofecoxib and celecoxib) mainly inhibit 'inducible' cyclooxygenase at the site of the inflammation, and do not influence 'constitutional' cyclooxygenase. COX-2 on the other hand, is constitutively expressed in the kidney and is responsible, at least in part, for the synthesis of some renal prostaglandins, 2, 3 thus influencing the sodium handling and renin release.
Nabumetone a non-acidic compound of alkanone class is a weak inhibitor of prostaglandin synthesis. It is well absorbed after oral administration and undergoes extensive hepatic first-class metabolism to form major metabolite 6-methoxy-2-naphtylacetic acid (6MNA), which is a more potent inhibitor of prostaglandin synthesis and is responsible for the anti-inflammatory activity of nabumetone. 4 Studies on endoscopy of the gastrointestinal tract have shown that all these drugs cause lower irritation of the gastric mucosa then indometacin and naproxen. [5] [6] [7] Previous studies have shown that treatment with NSAIDs may blunt the influence of some antihypertensives and cause a mild rise of arterial blood pressure. 8 The influence of rofecoxib and nabumetone on blood pressure, particularly among patients with hypertension, has still to be investigated.
The objective of this study was to determine the arterial blood pressure changes in patients treated with rofecoxib or nabumetone and suffering from stable arterial hypertension.
Patients and methods
Twenty patients suffering from stable essential arterial hypertension and knee OA were included in the study. Exclusion criteria included any contraindication to the use of rofecoxib or nabumetone, uncontrolled hypertension, creatinine range more then 1.5 mg/ml and likelihood of poor compliance with trial requirements. Ten patients (group 1) received 25 mg rofecoxib once daily in the morning for 30 days. Ten other patients received nabumetone 1.0 g twice daily in the first week of the treatment and 1.0 g once a day in the evening for the following 3 weeks. The medicine was given in accordance with manufacturers' instructions. All patients underwent 24-h ambulatory blood pressure monitoring (ABPM) at baseline and after 1 month using equipment validated by the Association for the Advancement of Medical Instrumentation (Profilomat, Disetronic Medical Systems AG, Burgdorf, Switzerland). 9 ABPM was performed on a regular working day with readings every 15 min throughout the daytime period and every 30 min throughout the night.
Statistical analysis
Results are presented as mean and standard deviation (s.d.). The mean quantitative values for the groups were compared using the one-tailed Student's t-test. A P value of Ͻ0.05 was considered statistically significant.
Results
Demographic and clinical data of the patients appears in Table 1 .
Patients treated with rofecoxib showed a mean systolic arterial pressure before treatment of 134.2 mm Hg, and 141.3 mm Hg (P = 0.1) afterwards, mean diastolic blood pressure before and after the treatment was 78.6 mm Hg and 82.7 mm Hg respectively (P = 0.13). While analysing systolic and diastolic blood pressure on daytime and night-time hours separately, we found that the mean systolic and diastolic characteristics of blood pressure showed no changes in the day time after the treatment (delta systolic BP −0.4 mm Hg and delta diastolic BP 0.4 mm Hg, P Ͼ 0.05), while nocturnal blood pressure was significantly increased: delta systolic BP was +15.7 mm Hg and delta diastolic BP was +8.5 mm Hg (P Ͻ 0.05).
In the nabumetone group the mean systolic arterial pressure before treatment was 129.1 mm Hg in the daytime and 121.0 mm Hg during the night. After the treatment the mean systolic arterial pressure raised to 132.0 mm Hg in the daytime and to 126.0 mm Hg at night (delta systolic BP was 2.9 mm Hg in the daytime and 5 mm Hg at night, P Ͼ 0.05). The mean diastolic arterial pressure also raised after the treatment: from 72.6 mm Hg to 75.8 mm Hg during the daytime and from 66.7 mm Hg to 72.0 mm Hg at night (delta diastolic BP −3.2 mm Hg and −4.9 mm Hg at day and night hours respectively, P Ͼ 0.05). The data is shown in Table 2 .
Discussion
Many studies have evaluated the effect of NSAIDs on blood pressure and on blood pressure control in treated hypertensive subjects. The mechanism of the pressor effect of NSAIDs remains speculative. Salt and water retention, 10 increased total peripheral vascular resistance due to inhibition of PGE2 and PGI2 11 or increased endothelin-1 secretion 12 are potentially important. It seems, that NSAID treatment increases blood pressure by 3-5 mm Hg. 13, 14 These effects are not the same for all NSAIDs. Among the drugs studied, indometacin and piroxicam seem to be associated with the largest increase in blood pressure, 15, 16 whereas ibuprofen was shown to have no effect on blood pressure in normotensive subjects. 17 There have recently been a few studies that investigated the affect of COX-2 specific NSAID on blood pressure. Some studies have shown an increase in blood pressure for both drugs celecoxib and rofecoxib. 18, 19 We did not find any other studies about the influence of nabumetone on blood pressure.
In our study we specifically investigated the affect of chronic rofecoxib and nabumetone treatment on patients with knee OA and comorbidity such as hypertension-the common combination in the general clinical practice. Our study showed that rofecoxib treatment blunted the effect of antihypertensive treatment during night-time hours, furthermore, it led to the disappearance of biological diurnal variation.
In most individuals, there is a circadian rhythm of blood pressure, with daytime levels being higher than night-time levels. This is related in part to changes in posture as well as diurnal changes of hormone activity, including renin-angiotensin system. It was shown earlier that elevated blood pressure during early morning hours could contribute to increased frequency of acute coronary events, stroke and sudden death. 20 The inhibition of COX-2 by rofecoxib, and thus inhibition of prostaglandin synthesis in the kidney of our patients may lead to the changes of renin-angiotensin and natrium homeostasis adversely influencing blood pressure control.
Nabumetone treatment caused moderate elevation in systolic and diastolic blood pressure during dayand night-time hours, but did not change the physiologic pattern of blood pressure. Probably because of the mild COX-2 inhibition activity of nabumetone, there was no strong influence on the renal prostaglandins and thus renin-angiotensin system. Therefore we did not see circadian rhythm changes in the patients treated with nabumetone.
Conclusions
Rofecoxib treatment did not change mean arterial blood pressure during day time hours in patients with stable arterial hypertension, however, during night-time hours systolic and diastolic blood pressure raised significantly, leading to a disappearance of physiological diurnal variation of blood pressure.
Nabumetone treatment caused a moderate increase of day-and night-time blood pressure, without changes in biological diurnal variation.
Our study was carried out on a small number of the patients. Further studies are needed in order to confirm these observations.
